Abera Bioscience
6.40 SEK
-2.29 %
Less than 1K followers
ABERA
Spotlight Stock Market
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-2.29 %
+10.34 %
-5.88 %
-5.88 %
-2.29 %
+9.97 %
+16.36 %
-39.05 %
-42.08 %
Abera Bioscience is a Swedish biotechnology company that develops nasal vaccines based on a proprietary OMV-based platform technology. The company's focus is on nasal vaccines that provide immune responses in both mucosal and systemic areas. Abera develops vaccines against several respiratory infectious diseases, including pneumococci, influenza and pandemic preparedness, with projects in preclinical and planned clinical phases. The company was founded in 2012 and is headquartered in Uppsala.
Read moreMarket cap
131.19M SEK
Turnover
53.71K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
12/5
2026
Interim report Q1'26
10/6
2026
General meeting '26
20/8
2026
Interim report Q2'26
All
Press releases
ShowingAll content types
Abera Bioscience publicerar presentation från Aktiespararnas Stora Aktiedagarna
Abera Bioscience AB Bokslutskommuniké 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools